SFSherise D. Ferguson

Sherise D. Ferguson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sherise D. Ferguson has a total of 303 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Surgical Management of Recurrent Brain Metastases: A Review

    by James W. Sampson, Eric A. Goethe, Sherise D. Ferguson

    As survival for cancer patients improves, the incidence of brain metastases has risen. This is likely due to improved systemic disease control, increased diligence in surveillance imaging in high-risk pathologies, improved neuro-imaging techniques and increased systemic screening for clinical trial enrollment. While there are well-established treatments for brain metastases, many patients will experience recurrence after definitive treatment. The management of these recurrent lesions is not well established and often varies on a per-patient basis, owing to the clinical complexity and variety of these patients. Patients with recurrent brain metastases have surgical procedural options to achieve local tumor control, including laser interstitial thermal therapy (LITT) repeat open surgical resection with or without placement of intracavity brachytherapy. Repeat resection can offer rapid improvement in neurological symptoms, performance status, and potentially survival. LITT is less invasive than a standard craniotomy but offers a chance at directed local treatment while still obtaining tissue for diagnostic purposes and achieving acceptable survival outcomes. Further study is needed to determine the role of LITT for recurrent brain metastases, but it is a useful tool, particularly for patients with deep-seated lesions who may not tolerate a large surgery. Intracavitary brachytherapy allows for the immediate delivery of highly conformal radiation to the surgical bed with excellent local control and low rates of radiation necrosis, even in previously irradiated patients. The decision regarding which of the above to employ for recurrent brain metastases will vary on a case-by-case basis, and further studies are needed to standardize their use for this growing problem.

  • Open Access

    Beyond motor: clinical manifestations of right hemisphere gliomas — a systematic review

    by Esteban Ramirez-Ferrer, Kyle Noll, Juliana Mayorga-Corvacho, Maria Alejandra Sierra, Charuta Furey, Alejandro Bugarini, Juan P. Zuluaga-Garcia, Priscella Asman, Chibawanye Ene, Sherise D. Ferguson, et al.


  • Open Access

    Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case Series

    by Christina Abi Faraj, Maxwell Tran, Sherise D. Ferguson, Maria A. Gubbiotti, Heather Y. Lin, Dima Suki, Nazanin Majd, Steven G. Waguespack, Ian E. McCutcheon

    Introduction: Pituitary carcinoma (PC) is a rare, aggressive endocrine neoplasm characterized by metastasis and challenging clinical management. The transformation from pituitary adenoma (PA) to PC is poorly understood, and predictors of metastasis remain elusive. This study evaluates the clinical course, surgical outcomes, and molecular characteristics of PC. Methods: We retrospectively reviewed patients with PC treated at the M. D. Anderson Cancer Center between 1993 and 2023. Primary outcomes included metastasis-free survival and overall survival (OS). Clinical features, radiographic findings, surgical strategies and outcomes, immunohistochemical profiles, and MIB-1 were analyzed. Results: The cohort (n = 20) had a median age at PA and PC diagnosis of 33.9 and 43.3 years, respectively. The median metastasis-free interval was 7.4 years. GH- and ACTH-secreting tumors showed shorter times to PC diagnosis, while nonfunctioning PAs had longer metastasis-free survival. PAs with MIB-1 > 10% had shorter survival. Dura was the most common site of metastasis within the CNS, and bone was the most common outside the CNS. Leptomeningeal disease was seen in six patients. PAs became aggressive > five years after initial surgical resection (n = 13) or metastasized early within the first five years (n = 7). Median OS from PA diagnosis was 13.7 years, and 8.6 years from PC diagnosis. A total of 102 neurosurgical procedures were performed, with a median of five per patient; the median was similar in patients surviving longer than five years vs. those whose survival was shorter (5.0 vs. 4.5 procedures, p = 0.661). Most surgical interventions post-PC diagnosis were for optic decompression or metastasectomy. All long-term survivors (at least five years after PC diagnosis) received temozolomide-based therapy, with most also receiving radiotherapy. Conclusions: PC shows a variable clinical course, with some PAs progressing to PC after years, while others transform rapidly. All long-term survivors received temozolomide-based therapy, most in combination with radiotherapy and repeated surgical intervention, suggesting that aggressive multimodal management may be associated with prolonged survival. Future research will focus on identifying reliable predictors of metastasis at different time points in the complex clinical evolution of these tumors.

  • Open Access

    Supplementary Figures1 from Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa Duose, Yujin Kudo, Banu Arun, et al.

  • Open Access

    Supplementary Table 1 from Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa Duose, Yujin Kudo, Banu Arun, et al.

  • Open Access

    Data from Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa Duose, Yujin Kudo, Banu Arun, et al.

    Purpose:Brain metastasis (BM) is a deadly complication of systemic malignancy that has been associated with defective cellular immunity. We sought to characterize the foundational elements and clinical relevance of BM-associated immunosuppression using integrated molecular profiling in primary patient material.Experimental Design:Retrospective patient tissue cohorts of breast (n = 153) and lung (n = 153) cancer BM were stratified by histopathologic scoring of tumor-infiltrating lymphocytes (TIL) and clinical outcome, with a large subset of breast cancer samples further analyzed by T-cell receptor sequencing (TCR-seq) and RNA sequencing (RNA-seq). An ongoing clinical trial comparing pre- and postoperative stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) in BM management was then leveraged to dissect radiation-induced immune responses by TCR- and RNA-seq.Results:Patients with high-grade histopathologic TIL infiltration and enriched TCR diversity demonstrated favorable prognoses in breast and lung cancer BM. Moreover, SRS/SRT treatment enhanced TCR diversity in the BM microenvironment, along with signatures of antigen processing and presentation. Finally, integrated analysis demonstrated that IR seemed to reactivate immune microenvironmental signatures normally suppressed in BM and upregulate immune signaling pathways correlated with favorable outcomes in patients with breast cancer BM.Conclusions:High TCR diversity in BM is associated with improved prognosis and highlights therapeutically tractable targets within the immune microenvironment. Moreover, we show in a prospective clinical trial that IR enhances T-cell–mediated immune responses, upregulating antigen presentation and enhancing TCR diversity in BM. These results argue for increased therapeutic investigations of radiation-induced immunomodulatory effects in BM, potentially in association with immune checkpoint inhibition.

  • Open Access

    Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana. Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa. Duose, Yujin Kudo, Banu Arun, et al.

    Purpose: Brain metastasis (BM) is a deadly complication of systemic malignancy that has been associated with defective cellular immunity. We sought to characterize the foundational elements and clinical relevance of BM-associated immunosuppression using integrated molecular profiling in primary patient material. Experimental Design: Retrospective patient tissue cohorts of breast (n = 153) and lung (n = 153) cancer BM were stratified by histopathologic scoring of tumor-infiltrating lymphocytes (TIL) and clinical outcome, with a large subset of breast cancer samples further analyzed by T-cell receptor sequencing (TCR-seq) and RNA sequencing (RNA-seq). An ongoing clinical trial comparing pre- and postoperative stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) in BM management was then leveraged to dissect radiation-induced immune responses by TCR- and RNA-seq. Results: Patients with high-grade histopathologic TIL infiltration and enriched TCR diversity demonstrated favorable prognoses in breast and lung cancer BM. Moreover, SRS/SRT treatment enhanced TCR diversity in the BM microenvironment, along with signatures of antigen processing and presentation. Finally, integrated analysis demonstrated that IR seemed to reactivate immune microenvironmental signatures normally suppressed in BM and upregulate immune signaling pathways correlated with favorable outcomes in patients with breast cancer BM. Conclusions: High TCR diversity in BM is associated with improved prognosis and highlights therapeutically tractable targets within the immune microenvironment. Moreover, we show in a prospective clinical trial that IR enhances T-cell–mediated immune responses, upregulating antigen presentation and enhancing TCR diversity in BM. These results argue for increased therapeutic investigations of radiation-induced immunomodulatory effects in BM, potentially in association with immune checkpoint inhibition.


  • Open Access

    Perioperative neurocognitive functioning in elderly patients undergoing awake craniotomy for high grade glioma

    by Eric A Goethe, Kyle R Noll, Subhiksha Srinivasan, Dima Suki, Sujit S Prabhu, Jeffrey S Weinberg, Ian E Mccutcheon, Chibawanye I Ene, Frederick F Lang, Shiao-Pei S Weathers, et al.

    Introduction: Older patients may be at particular risk of decline in neurocognitive function (NCF) following brain tumor resection, particularly when tumors are near-eloquent regions. Methods: We identified 95 patients of advanced age (≥60 years) with newly diagnosed, left hemisphere, high-grade eloquent glioma who underwent a first-time awake craniotomy for tumor resection. All patients had comprehensive neuropsychological evaluations preoperatively and a subset of patients (N = 45) completed postoperative assessment. Results: Median age at surgery was 66 years (range, 60-81) and tumors were most commonly located in the temporal (56%) and frontal (27%) lobes. Preoperatively, most patients exhibited NCF impairment on at least 1 neuropsychological test, most frequently in verbal learning (66%) and memory (71%). Localization in temporal regions conveyed greater impairment to memory, and patients with frontal tumors exhibited poorer executive functioning. Following awake resection, neurocognitive decline was most frequent in verbal learning (41%) and memory (38%). Postoperative change in neurocognitive performance was not associated with more advanced age, comorbidities, frailty, or tumor volume or extent of resection. Conclusions: Advanced age, frailty, and medical comorbidities were not significantly associated with poorer NCF outcome. Postoperative decline was greatest when patients present with high levels of baseline functioning and tumors involve the mesial temporal lobe. Importantly, rates of baseline impairment and postoperative decline in this older age sample were similar to other cohorts, including younger patients and lower grade tumors. Findings support the relative safety of awake craniotomy for resection of eloquent glioma in advanced age individuals.

  • Factors Associated With Overall Survival and 90-Day Mortality Following Resection of Melanoma Brain Metastases

    by Christina A. Faraj, Merve Hasanov, Denái R. Milton, Kalman A. Katlowitz, Subhiksha Srinivasan, Dima Suki, Eric A. Goethe, Sujit S. Prabhu, Chibawanye I. Ene, Jeffrey S. Weinberg, et al.

    BACKGROUND AND OBJECTIVES: Surgical decision making in patients with brain metastasis is complex, particularly for patients with melanoma brain metastasis (MBM). Few studies specifically address neurosurgical outcomes based on histology. This study aims to identify clinical factors associated with early mortality and overall survival (OS) after tumor resection in patients with MBM. METHODS: Patients diagnosed with MBM from 2009 to 2018 at our institution who underwent surgical resection as their first-line therapy were included in the study. The primary outcomes were postoperative OS, 90-day mortality, and leptomeningeal disease (LMD) incidence. Associations between OS and postoperative 90-day mortality with demographic/clinical factors were assessed using Cox proportional hazards regression models and logistic regression models, respectively. The cumulative incidence of LMD was determined using competing risks, and associations with demographic/clinical factors were assessed using proportional subdistribution hazards regression models. RESULTS: A total of 103 patients with MBM were included. Ninety-day mortality occurred in 18% (n = 19). Elevated lactate dehydrogenase at MBM diagnosis (odds ratio [OR] [95% CI]: OR = 7.17 [1.50-34.25]; P = .013) was associated increased odds of early mortality in multivariable analysis. Postoperative Karnofsky Performance Scale ≥80 (OR = 0.13 [0.03-0.62]; P = .010) and MBM at stage 4 diagnosis (OR = 0.11 [0.02-0.67]; P = .016) were associated with reduced odds of early mortality. Factors associated with better postoperative OS (hazard ratio [HR] [95% CI]) included synchronous diagnosis of MBM and stage 4 disease (HR = 0.59 [0.36-0.95]; P = .032), preoperative Karnofsky Performance Scale ≥80 (HR = 0.46 [0.27-0.80]; P = .006), adjuvant stereotactic radiosurgery (HR = 0.55 [0.32-0.93]; P = .026), and surgical reduction of volumetric intracranial tumor burden ≥95.6% (HR = 0.47 [0.28-0.80]; P = .005). No factors were significantly associated with cumulative incidence of LMD. CONCLUSION: This is the largest analysis of patients with MBM who underwent surgery as first-line therapy. We identified clinical factors associated with early postoperative mortality and survival including surgical reduction of intracranial tumor burden.

  • Open Access

    Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade

    by Renato A. Guerrieri, Grant M. Fischer, Jacob R. Cortez, Barbara G. Knighton, Debora A. Ledesma, Courtney W. Hudgens, Yimmy F. Delcid, Qianghua Hu, Christian Y. B. Onana, Fernando C. L. Carapeto, et al.

    Leptomeningeal disease (LMD) is a subtype of central nervous system metastatic disease that is associated with poor patient outcomes and limited treatment options. There is an unmet need to develop preclinical models of LMD to expedite and improve the development of new therapeutics. Here, we describe the development of multiple orthotopic immunocompetent murine models of melanoma LMD, including their use to assess the efficacy of systemic and/or intrathecal immunotherapy. LMD was established by direct intrathecal injection of murine cell lines (B16-F10, BP, D4M, D4M-UV2, MC38-gp100, RMS, YUMM3.1, and YUMMER1.7) into the cisterna magna of C57BL/6 mice. Tumor take rate, distribution, histology, peri-procedural mortality, and animal survival were assessed for each cell line. Intrathecal and systemic treatment with anti-PD1 were tested for safety, efficacy, and immune infiltration for LMD. Cisternal injection of murine melanoma cell lines successfully established LMD with low peri-procedural mortality, high tumor take rate, and varied survival duration across the panel of cell lines. Decreasing the total number of cells injected and increasing the volume of suspension of the injected cells increased the rate of distal spinal cord deposits, reflecting the common clinical distribution of LMD. Intrathecal administration of anti-PD1 in non-tumor bearing mice caused no morbidity or toxicity. Concurrent intrathecal and systemic anti-PD1 immunotherapy increased the survival of mice with murine melanoma LMD. We have established and characterized several immunocompetent murine models of LMD to facilitate the development and testing of new, more effective immunotherapy strategies for melanoma patients with LMD.